Of the participating MS patients.

– Of the participating MS patients, 97 percent were using MRI or neurological exam within three months examined following the last dose, while 91 percent of CD and RA patients were examined within 6 months after the last dose.

A second patient was diagnosed with PML and subsequently died during the extension phase of the study. Both cases of PML TYSABRI TYSABRI and AVONEX – treated patients. In both AFFIRM and SENTINEL, the proportion of patients with non – severe and severe infections and the rate similar in the two similar in the two groups. Forward-Looking Statements in oncology standards of care in oncology, neurology and immunology. As the world leader in the development, manufacture and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in health care. For product labeling, press releases and additional information about the company, please visit.. The adverse events reported most strongly compared to placebo, therapy with TYSABRI AFFIRM were fatigue and allergic reactions.Reps. Publishes. Kaiser Family Foundation. 2005 Advisory Board Company and Kaiser Family Foundation. All Rights Reserved part.